series-a
Stage
2
Investors
About
Switch Therapeutics develops biomarker-gated, innovative genetic medicines to transform the treatment of central nervous system diseases using its Conditionally Activated siRNA (CASi) platform, which combines single- and double-stranded RNAs for efficient self-delivery and uptake, potent gene knockdown, and cell selectivity.
Explore Switch Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.